The idea of blocking Tim-3-Tim-3L in conjunction with PD-1-PD-L1 blockade to correct tumour-induced T cell depletion/dysfunction in patients with advanced melanoma was further supported by this study. The gene discussed is HAVCR2; the disease is melanoma.